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Thyroid (SELECT) of patients with radioiodine-refractory differentiated thyroid cancer. This
exploratory analysis investigated potential predictive biomarkers of lenvatinib efficacy and
target engagement.
Patients and methods: Circulating cytokine/angiogenic factors (CAFs) in blood samples
collected at baseline and throughout treatment were analysed from patients randomised to
receive lenvatinib or placebo from August 5, 2011 to October 4, 2012. For CAF biomarker
analyses, patients were dichotomised by baseline levels. Tumour tissues were analysed for
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M. Tahara et al. / European Journal of Cancer 75 (2017) 213e221214Results: Tumours and CAFs were analysed from 183/392 (47%) and 387/392 (99%) patients,
respectively. Lenvatinib PFS benefit was maintained in all assessments. For lenvatinib-
treated patients, interaction-term analyses revealed that low baseline Ang2 level was predictive
of tumour shrinkage (Pinteraction Z 0.016) and PFS (Pinteraction Z 0.018). Vascular endothelial
growth factor and fibroblast growth factor 23 (FGF23) were significantly upregulated with
lenvatinib, and FGF23 upregulation on cycle 1/day 15 was associated with longer PFS. In mu-
tation analyses, no significant differences in clinical outcomes were observed. BRAFWT may be
a negative prognostic factor for PFS in placebo-treated patients with papillary thyroid cancer
(P Z 0.019).
Conclusion: The lenvatinib PFS benefit was maintained regardless of baseline CAF or BRAF/
RAS status. Baseline Ang2 was predictive of PFS in a subgroup of lenvatinib-treated patients,
indicating that Ang2 may be predictive of lenvatinib sensitivity. BRAFWT may be a poor prog-
nostic factor in patients with radioiodine-refractory papillary thyroid cancer. Improved PFS
associated with upregulated FGF23 suggests that lenvatinib-induced FGF receptor inhibition
contributes to lenvatinib efficacy.
Trial registration ID of the main study, SELECT: ClinicalTrials.gov: NCT01321554.
ª 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Tumour angiogenesis is essential to cancer cell survival,
local tumour growth, and development of distant me-
tastases [1]. Increased vascular endothelial growth fac-
tor (VEGF) expression is significantly associated with
angiogenesis and advanced-stage thyroid cancer [2];
therefore, the use of VEGF receptor (VEGFR) signal-
ling pathway inhibitors represented a rational and
attractive approach to control malignant thyroid can-
cer [3]. However, other molecular drivers of tumour
growth beyond VEGF-driven angiogenesis contribute
to the pathogenesis of cancer, including fibroblast
growth factor receptor (FGFR) signalling [4]. Such
pathways may provide escape mechanisms to VEGF-
targeted therapies and lead to the development of
resistance; this phenomenon has driven the develop-
ment of multitargeted kinase inhibitors, such as sor-
afenib and lenvatinib, which are approved for the
treatment of radioiodine-refractory differentiated thy-
roid cancer (RR-DTC).
Lenvatinib is an oral multikinase inhibitor of
VEGFR 1e3, FGFR 1e4, platelet-derived growth fac-
tor receptorealpha, and RET and KIT proto-oncogenes
[5e7]. Lenvatinib was approved for the treatment of
locally recurrent or metastatic, progressive RR-DTC in
the United States, Europe and Japan based on results
from the phase III Study of (E7080) LEnvatinib in
differentiated Cancer of the Thyroid (SELECT) trial [8].
SELECT was a global, randomised, double-blind,
multicenter, phase III study that demonstrated signifi-
cant improvements in progression-free survival (PFS)
and objective response rate (ORR) among patients with
RR-DTC treated with lenvatinib compared with pla-
cebo [8]. Median PFS was 18.3 months in lenvatinib-
treated patients versus 3.6 months in placebo-treatedpatients (hazard ratio [HR]: 0.21; 99% confidence in-
terval [CI]: 0.14e0.31; P < 0.001). ORR was 64.8% in
lenvatinib-treated patients versus 1.5% in placebo-
treated patients (P < 0.001).
To date, there are no established biomarkers that
are prognostic (for disease progression) or predictive
(for response to therapy) of benefit in RR-DTC or its
treatments. Several candidates of interest have been
proposed based on the mechanisms of action of
lenvatinib and the biology of DTC. Activation of the
RAS/RAF pathway has been reported to increase
VEGF production in thyroid cancer; however, it is still
unclear if RAS/RAF activation is associated with
tumour cell sensitivity to anti-VEGF therapy in thy-
roid cancer or other cancers [9].
Another molecular driver of tumour growth in the
pathogenesis of thyroid cancer is FGF/FGFR. Elevated
expression of FGF2, FGFR1, FGFR3 and FGFR4
have been detected in human thyroid carcinoma
compared with normal thyroid tissue [10,11]. The FGF/
FGFR pathway is part of an escape mechanism to
VEGF-targeted antiangiogenic therapies [4]. One mem-
ber of the FGF ligand family is FGF23, which is
secreted by osteocytes, and has a key role in phosphorus
homoeostasis and vitamin D metabolism [12]. Elevation
of FGF23 levels has been shown to be a surrogate
marker of FGFR1 inhibition [13].
Angiopoietin-2 (Ang2), a relatively novel regulator
of angiogenesis that acts through the TEK tyrosine
kinase, endothelial (Tie2) receptor, has been identified
as a potential prognostic biomarker for some types of
cancer, including hepatocellular carcinoma and mela-
noma, gastric, breast, bladder and prostate cancers [14].
The potential role of Ang2 as a predictive biomarker
has not yet been comprehensively tested in multi-
targeted tyrosine kinase inhibitors of VEGFR-2 in RR-
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have been conducted for other cancers. In one such
study, Ang2 was reported to be a predictive biomarker
for bevacizumab in patients with pancreatic cancer [15].
Exploratory analyses from previous phase II trials of
lenvatinib in medullary and differentiated thyroid can-
cers had identified associations between baseline Ang2
levels and patient outcomes, including ORR, PFS and
overall survival [16,17].
Therefore, BRAF, RAS, VEGFR-2, FGF23,
Ang2 and Tie2 were chosen for further investigation
based on these mechanistic rationales as well as prior
studies suggestive of possible predictive or prognostic
roles for these markers in phase II trials of lenvatinib in
thyroid cancer [16,17]. This exploratory analysis inves-
tigated potential baseline prognostic and predictive
biomarkers of lenvatinib efficacy and target engagement
from the phase III SELECT trial in patients with RR-
DTC to understand the efficacy of lenvatinib and the
nature of RR-DTC.
2. Materials and methods
The SELECT protocol and this study were approved by
the relevant Institutional Review Boards, in accordance
with the Good Clinical Practice guidelines and the
Declaration of Helsinki. All patients provided written
informed consent.
2.1. Patients and study design
SELECT (NCT01321554) methodology has been pub-
lished previously [8]. Briefly, patients had measurable,
pathologically confirmed DTC, evidence of radioiodine-
refractory disease and independently reviewed radio-
logic (IRR) evidence of progression within the previous
13 months. From August 5, 2011 to October 4, 2012,
eligible patients were randomised 2:1 to receive oral
lenvatinib (24 mg once daily) or placebo in continuous
28-day cycles. Patients were treated until IRR-verified
disease progression according to Response Evaluation
Criteria in Solid Tumours, version 1.1. The primary
data cutoff date was November 15, 2013.
2.2. Procedures
Patients’ blood samples were collected at baseline, cycle
1 day 15, day 1 of subsequent cycles, and at the end of
study treatment. Serum levels of circulating cytokine/
angiogenic factor (CAF) were measured using
commercially available enzyme-linked immunosorbent
assays (see Appendix A and Tables A. 1A and A. 1B).
Archival tumour-sample submission in SELECT was
optional and tumour samples were obtained from 220/
392 patients enrolled in SELECT. Of these patients, 190
had sufficient DNA for analysis and 183 passed the 500
depth of coverage threshold to be included in thecorrelative analyses. All samples were tested as a batch
analysis at the end of the study. Further details on
methods used are available inAppendixA andTableA. 2.2.3. Statistical analysis
CAF and thyroglobulin levels were examined for po-
tential correlations with maximum tumour shrinkage
(MTS; defined as maximum percentage change from
baseline in sum of diameters of target lesions), ORR and
PFS. For analyses of baseline levels of biomarker CAFs,
patients were dichotomised into low (first quartile) or
high group (all other quartiles), based on visual analysis
of the KaplaneMeier curves of baseline Ang2 quartiles,
which showed greater PFS ratio in the first quartile of
the lenvatinib treatment arm. Changes in biomarker
CAF levels were plotted for both placebo and lenvatinib
groups through cycle 9 day 1 of study treatment and at
treatment end. In analyses of pharmacodynamics asso-
ciations with PFS, patients were also dichotomised: low
(median ratio to baseline) versus high (>median ratio
to baseline).
Survival end-points were assessed using
KaplaneMeier estimates, and the influence of gene
mutations and circulating CAFs on PFS was analysed
using Cox proportional hazards model and log-rank
tests. Multivariate analysis of baseline patient charac-
teristics (age group, sex, region, race, ethnicity, baseline
thyroid-stimulating hormone levels, height, weight,
Eastern Cooperative Oncology Group performance
status, prior VEGF therapy, histology and histology
subtype) was conducted to confirm findings and adjust
for population bias.3. Results
The overall SELECT population comprised 392 pa-
tients: 261 were assigned to lenvatinib and 131 to pla-
cebo. Baseline tumour and blood samples were analysed
from 183/392 (47%) and 387/392 (99%) patients,
respectively. Archival tumour samples consisted of pri-
mary tumours (126/183; 69%), lymph node metastases
(26/183; 14%) and non-lymph node metastases (31/183;
17%). Patient demographics, baseline characteristics and
the primary end-point of PFS were generally similar
between the blood biomarker, tumour biomarker and
overall study populations (Table 1).
In this exploratory analysis, 26/123 (21.1%) patients
in the lenvatinib arm and 19/59 (32.2%) in the placebo
arm had tumours with a BRAF mutation, whereas 34/
122 (27.9%) patients in the lenvatinib arm and 7/60
(11.7%) patients in the placebo arm had tumours with a
RAS mutation (Table A. 3). Mutations in BRAF and
RAS were nearly exclusive; only 3 patients had both
BRAF and KRAS mutations (Fig. A. 1). Importantly,
the lenvatinib PFS benefit was observed for all
Table 1
Patient characteristics by analysis population.
Parameter ITT population
(n Z 392)
Tumour
biomarker
population
(n Z 183)
Blood
biomarker
population
(n Z 387)
Age, years,
mean (range)
61.9 (21e89) 61.3 (21e85) 61.9 (21e89)
Female, n (%) 192 (49) 80 (44) 189 (49)
ECOG performance status, n (%)
0e1 377 (96) 178 (97) 372 (96)
2e3 15 (4) 5 (3) 15 (4)
Histology, n (%)
Follicular, all 133 (34) 60 (33) 132 (34)
Hu¨rthle cell 58 (15) 25 (14) 58 (15)
Papillary, all 259 (66) 123 (67) 255 (66)
Poorly
differentiated
47 (12) 19 (10) 47 (12)
PFS HR (95% CI) 0.20
(0.15e0.27)
0.19
(0.12e0.28)
0.20
(0.15e0.26)
P-value 2.08  1034 9.06  1035 6.48  1019
CI, confidence interval; ECOG, Eastern Cooperative Oncology Group;
HR, hazard ratio; ITT, intent-to-treat; PFS, progression-free survival.
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tion status (Fig. 1). In contrast with our previous study
in patients from the phase II trial of lenvatinib in RR-
DTC [18], RAS mutations in the present analysis were
neither predictive of lenvatinib response nor prognostic
of PFS (Fig. 2A). Although the BRAF mutation also
was not predictive of lenvatinib response, it may be a
prognostic factor for better PFS among patients with
papillary thyroid cancer (PTC) who had developed
progressive RR-PTC (Fig. 2B); the significant associa-
tion between BRAF mutation and PFS was maintained
in both univariate (P Z 0.031) and multivariate
(P Z 0.0083) analyses in the placebo arm. These ana-
lyses were performed only for patients with PTCFig. 1. Forest plot of progression-free survival stratified by tumour mu
or placebo arm by BRAF or RAS tumour mutation status. CI, confi
MU, mutant; NE, not evaluable; PFS, progression-free survival; PTCbecause multiple studies, including the current study,
have demonstrated that BRAF mutations are extremely
rare in follicular thyroid cancer.
Baseline Ang2 levels correlated significantly with PFS
(P Z 0.0067; Table 2) in the placebo arm, and with
MTS, ORR and PFS in the lenvatinib arm (P < 0.0001
for each; Table 2; Fig. A. 2A and Fig. A. 2B). Baseline
VEGF levels correlated significantly with MTS,
ORR and PFS in the placebo arm (P Z 0.044,
P Z 0.038, and P Z 0.037, respectively; Table 2), and
with MTS (P Z 0.0082) and with ORR (P Z 0.0009;
Table 2) in the lenvatinib arm. Low baseline Ang2 level
was a predictive biomarker of MTS for lenvatinib-
treated patients (Pinteraction Z 0.016; Fig. A. 3). Both
univariate and multivariate analyses revealed a signifi-
cant separation in the PFS KaplaneMeier curves of
lenvatinib-treated patients with high versus low levels of
baseline Ang2, favouring patients with low baseline
Ang2 levels; and low baseline Ang2 levels were a positive
predictive factor for lenvatinib PFS (PinteractionZ 0.018;
Fig. 2C). Although ORR correlated significantly with
baseline Ang2 and VEGF levels, neither were predictive
of ORR to lenvatinib (Fig. A. 4A and Fig. A. 4B). The
baseline level of VEGF or Tie2 was not shown to be
prognostic or predictive of lenvatinib PFS (Fig. 2D and
E). Univariate and multivariate analyses also suggested
that high baseline thyroglobulin levels may be a prog-
nostic factor for poorer PFS in RR-DTC (P Z 0.027
and P Z 0.051, respectively) because a clear separation
in PFS curves was observed between placebo-treated
patients with high versus low baseline thyroglobulin
levels; this separation was absent among patients who
received lenvatinib (Fig. 2F).
In our pharmacodynamic analysis of changes in
serum biomarker levels with treatments, thyroglobulintation status. HRs and 95% CIs of PFS in patients in the lenvatinib
dence interval; FTC, follicular thyroid cancer; HR, hazard ratio;
, papillary thyroid cancer; WT, wild type.
Fig. 2. KaplaneMeier estimate of progression-free survival stratified by tumour mutation status or by low versus high levels of baseline
biomarkers. KaplaneMeier estimate of progression-free survival in patients in the lenvatinib or placebo arm by (A) RAS or (B) BRAF
tumour mutation status, (C) Ang2, (D) VEGF, (E) Tie2 and (F) thyroglobulin levels stratified by low (first quartile) versus high (all
other quartiles) baseline levels. Patients with both PTC and FTC were included in assessment of RAS mutation status, whereas only
patients with PTC were included in assessment of BRAF mutation status. Ang2, angiopoietin-2; FTC, follicular thyroid cancer;
L/LEN, lenvatinib; M, mutant; P/PBO, placebo; PTC, papillary thyroid cancer; Tie2, TEK tyrosine kinase, endothelial;
VEGF, vascular endothelial growth factor; W, wild type.
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Table 2
Correlation between baseline serum biomarker levels and clinical
outcomes.
Baseline Treatment Clinical outcome (P-value)
MTSa ORRb PFSc
Tie2 Placebo 0.067 0.33 0.030
Lenvatinib 0.65 0.99 0.038
Ang2 Placebo 0.068 0.27 0.0067
Lenvatinib 8.09  107 6.66  106 1.10  106
VEGF Placebo 0.044 0.038 0.037
Lenvatinib 0.0082 8.64  104 0.23
Tg Placebo 0.13 0.18 0.022
Lenvatinib 0.53 0.87 0.23
Ang2, angiopoietin-2; MTS, maximum tumour shrinkage;
ORR, objective response rate; PFS, progression-free survival;
Tie2, TEK tyrosine kinase, endothelial; Tg, thyroglobulin;
VEGF, vascular endothelial growth factor.
a Spearman rank correlation test.
b Wilcoxon signed-rank test.
c Univariate Cox proportional hazard model.
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lenvatinib, but increased in placebo recipients at each
treatment cycle tested (Fig. 3A). When this analysis was
subdivided by lenvatinib responders (complete response
or partial response) and non-responders (stable disease
[SD] or progressive disease [PD]), significantly lower
levels of thyroglobulin were seen in lenvatinib re-
sponders, but decreased thyroglobulin levels also were
observed in patients with SD or PD (Fig. 3B). Levels of
both VEGF and FGF23 increased significantly with
lenvatinib treatment at all time points tested and at the
end of treatment (Fig. 3C and D). Patients who expe-
rienced a greater increase in FGF23 levels (>median)
with lenvatinib treatment had longer PFS than patients
whose FGF23 increase was more modest (median;
Fig. A. 5A). However, there was no correlation between
the degree of increase in VEGF levels and PFS (Fig. A.
5B). In additional exploratory analyses, positive corre-
lations were found between serum levels of FGF23 and
phosphate, as expected (Table A. 4).
4. Discussion
This exploratory biomarker analysis of SELECT
demonstrated that the PFS benefit of lenvatinib
compared with placebo was maintained regardless of
baseline circulating-serum biomarker levels or BRAF/
RAS mutational status, indicating that lenvatinib is an
option for all eligible patients. It is important to clarify
that this does not indicate that lenvatinib would not be
beneficial for those patients with high levels of baseline
Ang2, because this subgroup of patients still had an
impressive HR (0.24) in SELECT. Rather, these results
suggest that a potential strategy for improved efficacy
could be explored in these patients (e.g. the combination
of lenvatinib with inhibitors targeting the Ang2/Tie2
signalling pathway). The Ang2/Tie2 signalling pathwayis considered a potential target to improve anti-
angiogenic therapy; however, the role of Ang2 in DTC
has not yet been established [19]. This study provides
new insight to improve clinical outcome over VEGF-
targeted therapy alone.
Changes in baseline levels of VEGF and FGF23 are
pharmacodynamic biomarkers for the inhibition of
VEGF and FGF signalling pathways [13,20]. Along
with VEGF levels, FGF23 levels increased consistently
in the lenvatinib arm, suggestive of lenvatinib-
mediated VEGFR and FGFR target engagement and
signalling inhibition in these patients with RR-DTC
from SELECT. To our knowledge, this is the first
report of a tyrosine-kinase-inhibitoremediated in-
crease in FGF23 levels in a phase III study. In addi-
tion, the observed PFS improvement in patients with
greater increases in FGF23 levels while receiving len-
vatinib is suggestive of the essential role of FGFR
inhibition on lenvatinib efficacy in patients with RR-
DTC. Positive correlations between serum phosphate
and FGF23 levels were expected and observed,
reflecting the role of FGF23 in the regulation of
phosphorus homoeostasis, and potentially confound-
ing our interpretations of the FGF23 findings. Further
exploration of the changes in serum phosphorus level
and its relationship with FGF23 levels is warranted.
Overall, these results indicate that inhibition against
the FGFR signalling pathways (in addition to
VEGFR) represents a promising and important
approach to controlling RR-DTC.
The similar PFS HRs and 95% CIs between the
blood biomarker, tumour biomarker and overall study
populations illustrate that the biomarker study pop-
ulations in this investigation were a robust representa-
tion of the overall SELECT population. Surprisingly,
although neither BRAF nor RAS mutations were pre-
dictive nor prognostic biomarkers in the overall popu-
lation of patients with DTC, BRAFWT was a prognostic
factor for poorer PFS in metastatic progressive RR-
PTC with placebo in this analysis. Our observation
that the prognosis for patients with RR-PTC and
BRAFWT is worse in the absence of therapy strengthens
the argument for prompt initiation of VEGFR-targeted
treatment, especially because BRAF inhibitors are not a
therapeutic option for this subset of patients. This
finding was also seen in the phase III study of sorafenib
in locally advanced metastatic patients with radioactive
iodine refractory thyroid cancer (Study of Sorafenib in
Locally Advanced or Metastatic Patients with RAI-
Refractory Thyroid Cancer, DECISION), and sug-
gests that in metastatic progressive RR-PTC, BRAFWT
may be prognostic for poorer PFS in the placebo arm
[21]. Our findings also raise questions of possible
coexisting mutations, as well as changes or evolution in
mutational profile from the initial tumour to the
radioiodine-refractory metastatic disease. This supports
the importance of obtaining genomic data from tumour
Fig. 3. Changes in (A) biomarker levels for thyroglobulin by treatment arm: placebo versus lenvatinib, (B) thyroglobulin levels by
response: complete/partial responders versus patients with stable/progressive disease (lenvatinib arm only), (C) VEGF and (D) FGF23
levels by treatment arm: lenvatinib versus placebo. Cx Dx, cycle # day # of treatment; CI, confidence interval; CR, complete response;
FGF, fibroblast growth factor; PR, partial response; VEGF, vascular endothelial growth factor.
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note, no central review of histology was performed in
SELECT, and poorly differentiated carcinomas (which
have low frequency of BRAF-mutated genes and higher
frequency of RAS-mutated genes [23,24]) were classified
as PTC, which may also explain our results. It is also
important to note that the low frequency of BRAF-
mutant tumours in this study limits our conclusions.
Finally, TERT promoter mutations (which were not
tested in the current study) in synergy with BRAF mu-
tations have recently emerged as a novel genetic back-
ground in aggressive forms of thyroid cancer, andshould be investigated in further studies of RR-DTC
biomarkers [25,26].
Our analysis indicates that a rapid decrease in
thyroglobulin levels occurs with lenvatinib treatment,
consistent with the rapid tumour response observed with
lenvatinib [8]. In addition, the magnitude of change in
thyroglobulin levels appear to be associated with
objective responses; however, a decrease in thyroglob-
ulin levels also was observed in patients with SD or PD.
Therefore, although thyroglobulin is possibly a prog-
nostic marker, it is an unreliable biomarker of lenvatinib
response, underlining the importance of regular tumour
M. Tahara et al. / European Journal of Cancer 75 (2017) 213e221220assessments to monitor patients on therapy (as opposed
to reliance on thyroglobulin alone).
This study had several limitations, the foremost being
the exploratory nature of the analysis, which, for
example, led to imbalances in the distribution of RAS
mutants in the lenvatinib versus placebo arms. In addi-
tion, it should be noted that at the time of analysis, many
patients were continuing treatment with lenvatinib;
therefore, future correlative analyses with a more mature
data set may provide more robust observations, partic-
ularly with regard to overall survival outcomes. Addi-
tionally, only 183 (46.7%) of SELECT patient tumours
could be analysed for RAS and BRAF mutations, and
only 57/183 (31.3%) tumours were from metastatic sites.
In conclusion, all lenvatinib-treated patients in the
SELECT trial, regardless of baseline circulating-serum
biomarker levels or BRAF/RAS mutational status,
derived a PFS benefit compared with placebo. In pa-
tients with RR-DTC treated with lenvatinib, FGFR
inhibition in addition to VEGFR blockade is likely to
play a role in improving PFS. Further study of new
treatments or combination therapies to further improve
PFS in patients with BRAFWT RR-PTC or RR-DTC
with high baseline Ang2 levels is warranted.Role of the funding source
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